Skip to main content
SpringerLink
Log in

A Validated, Specific Stability-Indicating RP-LC Method for Moxifloxacin and Its Related Substances

  • Full Short Communication
  • Published:
Chromatographia Aims and scope Submit manuscript

Abstract

A validated, specific, stability-indicating reversed-phase liquid chromatographic method has been developed for quantitative analysis of moxifloxacin and its related substances in bulk samples and pharmaceutical dosage forms in the presence of degradation products and process-related impurities. Forced degradation studies were performed on bulk samples of moxifloxacin, in accordance with ICH guidelines, using acidic, basic, and oxidizing conditions, and thermal and photolytic stress, to show the stability-indicating power of the method. Significant degradation was caused by oxidative stress and by basic conditions; no degradation was observed under the other stress conditions. The method was optimized by analysis of the samples generated during the forced degradation studies and sample solutions spiked with the impurities. Good resolution between the analyte peak and peaks corresponding to process-related impurities and degradation products was achieved on a C18 column with a simple linear mobile phase gradient prepared from aqueous sodium dihydrogen orthophosphate dihydrate containing triethylamine, pH adjusted to 3.0 with orthophosphoric acid, and methanol. Detection was performed at 240 nm. Limits of detection and quantification were established for moxifloxacin and its process related impurities. When the stressed test solutions were assayed against moxifloxacin working standard solution the mass balance was always between 99.3 and 100.1%, indicating the method was stability-indicating. The method was validated in accordance with ICH guidelines, and found to be suitable for checking the quality of bulk samples of moxifloxacin at the time of release of a batch and during storage (long term and accelerated stability testing was conducted).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Gore J, Bryant Z, Stone MD, Nollmann M, Cozzarelli NR, Bustamante C (2006) Nature 439:100–104. doi:10.1038/nature04319

    Article  CAS  Google Scholar 

  2. Arteseros AH, Barbosa J, Compañó R (2002) J Chromatogr A 945:1–24. doi:10.1016/S0021-9673(01)01505-9

    Article  Google Scholar 

  3. Lorian V (ed) (1996) Antibiotics in laboratory medicine, 4th edn. Williams and Wilkins, Baltimore, pp 591–592

  4. Samanidou VF, Demetriou CE, Papadoyannis IN (2003) Anal Bioanal Chem 375:623–629

    CAS  Google Scholar 

  5. Barman Balfour JA, Wiseman LR (1999) Drugs 57:363. doi:10.2165/00003495-199957030-00007

    Article  Google Scholar 

  6. Laban-Djurdjević A, Jelikić-Stankov M, Djurdjević P (2006) J Chromatogr B Analyt Technol Biomed Life Sci 844(1):104–111. doi:10.1016/j.jchromb.2006.07.001

    Article  Google Scholar 

  7. Vishwanathan K, Bartlett MG, Stewart JT (2002) J Pharm Biomed Anal 30(4):961–968. doi:10.1016/S0731-7085(02)00393-X

    Article  CAS  Google Scholar 

  8. ICH (1994) Text on validation of analytical procedures, Q2A, International Conference on Harmonization, IFPMA, Geneva

  9. Bakshi M, Singh S (2002) J Pharm Biomed Anal 28:1011–1040. doi:10.1016/S0731-7085(02)00047-X

    Article  CAS  Google Scholar 

  10. ICH (1996) Photostability testing of new drug substances and products Q1B, International Conference on Harmonization, IFPMA, Geneva

  11. Draft International Harmonization of Pharmacopoeias (1993) Text on validation of analytical procedures. Pharmaeuropa 5(4):341

    Google Scholar 

  12. Ribani M, Bottoli CBG, Collins CH, Jardim ISF, Melo LFC (2004) Quim Nova 27:771. doi:10.1590/S0100-40422004000500017

    CAS  Google Scholar 

  13. United States Pharmacopeia (2000) Validation of compendial methods, 24th edn. USP 24, Sect. 1225

  14. Centre for Drug Evaluation and Research (1994) Validation of chromatographic methods; reviewer guidance. Centre for Drug Evaluation and research (CDER), November 1994, CMC 3

  15. ICH (2003) Stability testing of new drug substances and products Q1A (R2). International Conference on Harmonization, IFPMA, Geneva

Download references

Acknowledgments

The authors wish to thank the management of United States Pharmacopeia-India Private Limited group for supporting this work. We would also like to thank colleagues in separation science division of Analytical Research of United States Pharmacopeia-India Private Limited for their cooperation in carrying out this work.

Author information

Authors and Affiliations

  1. Reference Standard Laboratory, United States Pharmacopeia-India Private Limited, ICICI Knowledge Park, Turkapally, Shameerpet, Hyderabad, 500 078, India

    M. Lalitha Devi

  2. Department of Chemistry, J.N.T.U. College of Engineering, Anantapur, 515002, India

    K. B. Chandrasekhar

Authors
  1. M. Lalitha Devi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. B. Chandrasekhar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Lalitha Devi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lalitha Devi, M., Chandrasekhar, K.B. A Validated, Specific Stability-Indicating RP-LC Method for Moxifloxacin and Its Related Substances. Chroma 69, 993–999 (2009). https://doi.org/10.1365/s10337-009-1061-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1365/s10337-009-1061-8

Keywords

Search

Navigation